Skip to main content

Table 4 Comparison between patients with viridans streptococcal bacteremia susceptible to cefepime and those not susceptible to cefepime

From: Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children

Factor

Susceptible to cefepime (n=159)

Not susceptible to cefepime (n=40)

p-value

Age (years)

38 (20-51)

17 (2-51)

0.013

Gender (male)

89 (56.0)

19 (47.5)

0.456

Underlying disease

  

0.320

 Acute myeloid leukemia

117 (73.6)

28 (70.0)

 

 Acute lymphoblastic leukemia

26 (16.4)

9 (22.5)

 

 Other leukemias

6 (3.1)

1 (2.5)

 

 Non-Hodgkin lymphoma

8 (5.0)

1 (2.5)

 

 Multiple myeloma

2 (1.3)

1 (2.5)

 

Complete remission status

104 (65.4)

19 (47.5)

0.037

Preceding therapy

  

0.732

 Conventional chemotherapy

151 (95.0)

38 (95.0)

 

 Hematopoietic cell transplantation

   

  Autologous

6 (3.8)

2 (5.0)

 

  Allogeneic

2 (1.3)

0 (0.0)

 

Duration after the preceding therapy (days)

12 (10-14)

13 (10-13)

0.568

Antibacterial prophylaxis*

  

<0.001

 None

4 (2.5)

1 (2.7)

 

 Trimethoprim/sulfamethoxazole

31 (19.5)

20 (54.1)

 

 Ciprofloxacin

124 (78.0)

16 (43.2)

 

Probability of antibacterial therapy after chemotherapy† (%)

84.0 ± 29.6

81.8 ± 32.0

0.864

Previous antibacterial therapy for febrile neutropenia† (times)

1 (1-2)

2 (1-2)

0.284

Accompanying symptoms

   

 Oral mucositis

35 (22.0)

6 (15.0)

0.327

 Cough

18 (11.3)

2 (5.0)

0.377

 Sputum

6 (3.8)

3 (7.5)

0.388

 Rhinorrhea

1 (0.6)

0 (0.0)

1.000

 Diarrhea

50 (31.4)

8 (20.0)

0.154

 Abdominal pain

34 (21.4)

4 (10.0)

0.102

Polymicrobial infection

   

  Other bacterial infection

17 (10.7)

5 (12.5)

0.779

  Fungal infection

16 (10.1)

2 (5.0)

0.537

Complications attributable to VSB

23 (14.5)

3 (7.5)

0.243

 Ventilator care

8 (5.0)

0 (0.0)

0.362

 Acute respiratory distress syndrome

6 (3.8)

0 (0.0)

0.602

 Shock

23 (14.5)

3 (7.5)

0.243

 Death

4 (2.5)

0 (0.0)

0.585

Overall death

13 (8.2)

1 (2.5)

0.309

Laboratory findings

   

 White blood cell count (/μL)

60 (20-160)

40 (20-118)

0.194

 Absolute neutrophil count (/μL)

0 (0-0)

0 (0-0)

0.915

 Duration of neutropenia before the diagnosis of VSB (days)

5 (4-7)

7 (5-11)

0.021

 Total duration of neutropenia (days)

16 (12-23)

20 (12-24)

0.094

 Peak C-reactive protein level (mg/dL)

19.6 (13.1-26.1)

17.1 (9.3-28.1)

0.397

  1. Data are median (inter quartile range), mean ± SD, or No. (%) of cases.
  2. VSB viridans streptococcal bacteremia.
  3. *Antibacterial prophylaxis was evaluated in 196 patients (159 with viridans streptococcal bacteremia susceptible to cefepime, 37 with viridans streptococcal bacteremia not susceptible to cefepime) except 3 patients who had been undergoing ceftazidime treatment and 3 patients in whom cefepime susceptibility tests were not done.
  4. †Information on previous chemotherapies and antibacterial therapies was completely reviewed in 166 patients (137 with viridans streptococcal bacteremia susceptible to cefepime, 29 with viridans streptococcal bacteremia not susceptible to cefepime).
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us